Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib 1 vs 2 Years Maintenance in Ovarian Cancer
NCT06580314Phase 3Recruiting
- Sponsor
- NRG Oncology
- Start
- Mar 2025
- Primary completion
- Dec 2034
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of olaparib in ovarian cancer, sponsored by NRG Oncology. Started Mar 2025; status: recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06580314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06580314.